{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:52Z","timestamp":1791478252455,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40121-026-01381-w","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:17:42Z","timestamp":1782285462000},"page":"2319-2334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glecaprevir\/Pibrentasvir for Acute Hepatitis C Virus Infection in Individuals with a History of Prior Hepatitis C Infection"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04903626","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christoph","family":"Boesecke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Workowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbra","family":"Cave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marcinak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Semizarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Welhaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Baumgarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"1381_CR1","unstructured":"World Health Organization. Global Hepatitis Report 2024: action for access in low- and middle-income countries. https:\/\/iris.who.int\/handle\/10665\/376461. Accessed Dec 2025."},{"key":"1381_CR2","unstructured":"Centers for Disease Control. Hepatitis C surveillance. https:\/\/www.cdc.gov\/hepatitis-surveillance-2022\/hepatitis-c\/. Accessed Feb 2025."},{"issue":"10","key":"1381_CR3","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/cid\/ciac272","volume":"75","author":"JM Johannesson","year":"2022","unstructured":"Johannesson JM, Fridriksdottir RH, Love TJ, et\u00a0al. High rate of hepatitis C virus reinfection among recently injecting drug users: results from the TraP Hep C program\u2014a prospective nationwide, population-based study. Clin Infect Dis. 2022;75(10):1732\u20139.","journal-title":"Clin Infect Dis"},{"key":"1381_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.855989","volume":"10","author":"Z Wan","year":"2022","unstructured":"Wan Z, Sun P, Dzakah EE, Huang L, Shuai P, Liu Y. Reinfection rate of hepatitis C in HIV-1 positive men who have sex with men: a systematic review and meta-analysis. Front Public Health. 2022;10:855989.","journal-title":"Front Public Health"},{"key":"1381_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/QAI.0000000000003660","volume":"99","author":"A Chaillon","year":"2025","unstructured":"Chaillon A, Gaitan NC, Taylor LE, et\u00a0al. Predictors of acute HCV incidence in people with HIV: insights from a long-term cohort study. J Acquir Immune Defic Syndr. 2025;99:288\u201392.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"1381_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/cid\/ciaa645","volume":"73","author":"AM Newsum","year":"2021","unstructured":"Newsum AM, Matser A, Schinkel J, et\u00a0al. Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: a longitudinal analysis. Clin Infect Dis. 2021;73(3):460\u20137.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1381_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009916","volume":"17","author":"G Danesh","year":"2021","unstructured":"Danesh G, Virlogeux V, Ramiere C, Charre C, Cotte L, Alizon S. Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data. PLoS Pathog. 2021;17(9):e1009916.","journal-title":"PLoS Pathog"},{"issue":"6","key":"1381_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","volume":"4","author":"A Trickey","year":"2019","unstructured":"Trickey A, Fraser H, Lim AG, et\u00a0al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435\u201344.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1381_CR9","unstructured":"American Association for the Study of Liver Diseases-Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. https:\/\/www.hcvguidelines.org\/. Accessed May 2026."},{"issue":"5","key":"1381_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series(\u2606). J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"key":"1381_CR11","unstructured":"European AIDS Clinical Society. EACS guidelines. https:\/\/eacs.sanfordguide.com\/. Accessed May 2026."},{"key":"1381_CR12","unstructured":"Bhattacharya D, Aronsohn A, Price J, Lo Re V, Panel A-IHG. Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023. (in press)."},{"issue":"2","key":"1381_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/v17020163","volume":"17","author":"L Di Marco","year":"2025","unstructured":"Di Marco L, Cannova S, Ferrigno E, et\u00a0al. A comprehensive review of antiviral therapy for hepatitis C: the long journey from interferon to pan-genotypic direct-acting antivirals (DAAs). Viruses. 2025;17(2):163.","journal-title":"Viruses"},{"issue":"1","key":"1381_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hep.31003","volume":"72","author":"M Martinello","year":"2020","unstructured":"Martinello M, Orkin C, Cooke G, et\u00a0al. Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. Hepatology. 2020;72(1):7\u201318.","journal-title":"Hepatology"},{"issue":"4","key":"1381_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2021.04.056","volume":"75","author":"GV Matthews","year":"2021","unstructured":"Matthews GV, Bhagani S, Van der Valk M, et\u00a0al. Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021;75(4):829\u201339.","journal-title":"J Hepatol"},{"issue":"3","key":"1381_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100650","volume":"5","author":"B Maasoumy","year":"2023","unstructured":"Maasoumy B, Ingiliz P, Spinner CD, et\u00a0al. Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: the HepNet acute HCV-V study. JHEP Rep. 2023;5(3):100650.","journal-title":"JHEP Rep"},{"issue":"3","key":"1381_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/HEP.0000000000000923","volume":"81","author":"S Pol","year":"2025","unstructured":"Pol S, Thompson AJ, Collins M, et\u00a0al. Effectiveness and safety of glecaprevir\/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: a single-arm retrospective study. Hepatology. 2025;81(3):1006\u201318.","journal-title":"Hepatology"},{"key":"1381_CR18","unstructured":"AbbVie. MAVYRET (glecaprevir and pibrentasvir). US Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209394s016,215110s003lbl.pdf. Accessed May 2026."},{"issue":"4","key":"1381_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2025.11.009","volume":"84","author":"JM Llibre","year":"2026","unstructured":"Llibre JM, Boesecke C, Moon J, et\u00a0al. A single-arm phase IIIb study of 8-week glecaprevir\/pibrentasvir treatment in adults with acute hepatitis C. J Hepatol. 2026;84(4):702\u201312.","journal-title":"J Hepatol"},{"issue":"1","key":"1381_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000200","volume":"23","author":"RG Kim","year":"2024","unstructured":"Kim RG, Price JC. A framework for approaching hepatitis C reinfection in people who use drugs. Clin Liver Dis. 2024;23(1):e0200.","journal-title":"Clin Liver Dis"},{"issue":"5","key":"1381_CR21","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/cid\/ciz949","volume":"71","author":"P Ingiliz","year":"2020","unstructured":"Ingiliz P, Wehmeyer MH, Boesecke C, et\u00a0al. Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: current incidence rates, compared with rates during the interferon era. Clin Infect Dis. 2020;71(5):1248\u201354.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1381_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jhep.2019.11.022","volume":"72","author":"E Hoornenborg","year":"2020","unstructured":"Hoornenborg E, Coyer L, Boyd A, et\u00a0al. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. J Hepatol. 2020;72(5):855\u201364.","journal-title":"J Hepatol"},{"issue":"6","key":"1381_CR23","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/cid\/ciae297","volume":"79","author":"DS Fierer","year":"2024","unstructured":"Fierer DS, Carollo JR, Rodriguez-Caprio G, et\u00a0al. Hepatitis C virus reinfection among men who have sex with men with HIV in New York City. Clin Infect Dis. 2024;79(6):1420\u20137.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1381_CR24","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1097\/QAD.0000000000003651","volume":"37","author":"M Martinello","year":"2023","unstructured":"Martinello M, Carson JM, Van Der Valk M, et\u00a0al. Reinfection incidence and risk among people treated for recent hepatitis C virus infection. AIDS. 2023;37(12):1883\u201390.","journal-title":"AIDS"},{"issue":"8","key":"1381_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.30024","volume":"7","author":"AH Litwin","year":"2024","unstructured":"Litwin AH, Tsui JI, Heo M, et\u00a0al. Hepatitis C virus reinfection among people who inject drugs: long-term follow-up of the HERO study. JAMA Netw Open. 2024;7(8):e2430024.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1381_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/cid\/civ948","volume":"62","author":"B Simmons","year":"2016","unstructured":"Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683\u201394.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1381_CR27","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1111\/liv.14976","volume":"41","author":"P Huang","year":"2021","unstructured":"Huang P, Wang Y, Yue M, et\u00a0al. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: a comprehensive analysis. Liver Int. 2021;41(10):2341\u201357.","journal-title":"Liver Int"},{"issue":"2","key":"1381_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"M Puoti","year":"2018","unstructured":"Puoti M, Foster GR, Wang S, et\u00a0al. High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis. J Hepatol. 2018;69(2):293\u2013300.","journal-title":"J Hepatol"},{"key":"1381_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.drugalcdep.2018.11.007","volume":"194","author":"GR Foster","year":"2019","unstructured":"Foster GR, Dore GJ, Wang S, et\u00a0al. Glecaprevir\/pibrentasvir in patients with chronic HCV and recent drug use: an integrated analysis of 7 phase III studies. Drug Alcohol Depend. 2019;194:487\u201394.","journal-title":"Drug Alcohol Depend"},{"key":"1381_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.drugpo.2019.01.011","volume":"66","author":"J Grebely","year":"2019","unstructured":"Grebely J, Dore GJ, Alami NN, et\u00a0al. Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy. 2019;66:73\u20139.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"1381_CR31","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1016\/j.cgh.2020.06.044","volume":"18","author":"E Zuckerman","year":"2020","unstructured":"Zuckerman E, Gutierrez JA, Dylla DE, et\u00a0al. Eight weeks of treatment with glecaprevir\/pibrentasvir is safe and efficacious in an integrated analysis of treatment-naive patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2020;18(11):2544-53 e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"1381_CR32","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/jvh.13160","volume":"26","author":"M Ragonnet-Cronin","year":"2019","unstructured":"Ragonnet-Cronin M, Hostager R, Hedskog C, Osinusi A, Svarovskaia E, Wertheim JO. HIV co-infection is associated with increased transmission risk in patients with chronic hepatitis C virus. J Viral Hepat. 2019;26(11):1351\u20134.","journal-title":"J Viral Hepat"},{"issue":"10","key":"1381_CR33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1086\/497131","volume":"41","author":"Y Yazdanpanah","year":"2005","unstructured":"Yazdanpanah Y, De Carli G, Migueres B, et\u00a0al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case\u2013control study. Clin Infect Dis. 2005;41(10):1423\u201330.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1381_CR34","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/cid\/ciz022","volume":"69","author":"E Gane","year":"2019","unstructured":"Gane E, Poordad F, Zadeikis N, et\u00a0al. Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1\u20136 hepatitis C virus infections and compensated liver disease. Clin Infect Dis. 2019;69(10):1657\u201364.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1381_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/2050640619835394","volume":"7","author":"D Chromy","year":"2019","unstructured":"Chromy D, Mandorfer M, Bucsics T, et\u00a0al. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United Eur Gastroenterol J. 2019;7(4):507\u201316.","journal-title":"United Eur Gastroenterol J"},{"issue":"12","key":"1381_CR36","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1097\/00002030-199012000-00016","volume":"4","author":"E Chamot","year":"1990","unstructured":"Chamot E, Hirschel B, Wintsch J, et\u00a0al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS. 1990;4(12):1275\u20137.","journal-title":"AIDS"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01381-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01381-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01381-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:24:10Z","timestamp":1786728250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01381-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01381-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Christoph Boesecke received honoraria for consulting or speaking at educational events from Gilead, AbbVie, MSD, ViiV\/GSK, Pfizer, AstraZeneca, and Bavarian Nordic. Kimberly Workowski received institutional research funding from AbbVie. Stuart C. Gordon received honoraria for consulting or speaking from Gilead, Ipsen, AbbVie, and Mirum. Barbra Cave, John Marcinak, Michael G. Miller, Dimitri Semizarov, and Anne Welhaven are employees of AbbVie and may own stock. Axel Baumgarten received honoraria for consulting or speaking at educational events from Gilead, AbbVie, MSD, ViiV\/GSK, Pfizer, and AstraZeneca.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on a previously conducted study [\n                      \n                      ], which was performed in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and principles of the Declaration of Helsinki or the laws and regulations of the regions in which the research was performed. The study was approved by the institutional review boards or independent ethics committees of the participating sites. Written informed consent was obtained from all study participants.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}